The APP Arctic mutation (E693G) is a pathogenic mutation in the [amyloid precursor protein](/proteins/app-protein) gene that causes familial [Alzheimer's disease](/diseases/alzheimers-disease). Unlike other APP mutations that increase [Aβ](/proteins/amyloid-beta) production, the Arctic mutation enhances Aβ aggregation and protofibril formation. This mutation was instrumental in shifting research focus toward Aβ oligomers as the true toxic species in AD. [@reactive]
Overview
The APP Arctic mutation (E693G) is a pathogenic mutation in the [amyloid precursor protein](/proteins/app-protein) gene that causes familial Alzheimer's disease. Unlike other APP mutations that increase Aβ production, the Arctic mutation enhances Aβ aggregation and protofibril formation. This mutation was instrumental in shifting research focus toward Aβ oligomers as the true toxic species in AD. [@reactive]
Genetic Background
Gene: APP (Amyloid Precursor Protein)
Chromosome: 21q21.3
Mutation: E693G (Glu693Gly)
cDNA Change: c.2128A>G
Discovery: 1998, Swedish family (Nordstedt et al.)
Inheritance: Autosomal dominant
Mechanism
Effect on APP Processing
Location: Within the Aβ sequence (Aβ position 22)
Effect: Does NOT significantly increase total Aβ production
Primary effect: Alters Aβ aggregation properties
Aβ Alterations
...
APP Arctic Mutation (APP Arctic)
The APP Arctic mutation (E693G) is a pathogenic mutation in the [amyloid precursor protein](/proteins/app-protein) gene that causes familial [Alzheimer's disease](/diseases/alzheimers-disease). Unlike other APP mutations that increase [Aβ](/proteins/amyloid-beta) production, the Arctic mutation enhances Aβ aggregation and protofibril formation. This mutation was instrumental in shifting research focus toward Aβ oligomers as the true toxic species in AD. [@reactive]
Overview
The APP Arctic mutation (E693G) is a pathogenic mutation in the [amyloid precursor protein](/proteins/app-protein) gene that causes familial Alzheimer's disease. Unlike other APP mutations that increase Aβ production, the Arctic mutation enhances Aβ aggregation and protofibril formation. This mutation was instrumental in shifting research focus toward Aβ oligomers as the true toxic species in AD. [@reactive]
Genetic Background
Gene: APP (Amyloid Precursor Protein)
Chromosome: 21q21.3
Mutation: E693G (Glu693Gly)
cDNA Change: c.2128A>G
Discovery: 1998, Swedish family (Nordstedt et al.)
Inheritance: Autosomal dominant
Mechanism
Effect on APP Processing
Location: Within the Aβ sequence (Aβ position 22)
Effect: Does NOT significantly increase total Aβ production
Primary effect: Alters Aβ aggregation properties
Aβ Alterations
Production: Normal or slightly reduced
Aggregation: Markedly accelerated
Protofibrils: Increased formation of toxic Aβ protofibrils
Aβ aggregation kinetics are critical to pathogenesis
Protofibrils and oligomers may be more toxic than plaques
Clinical Significance
Age of Onset
Typical onset: 55-70 years
Similar to sporadic AD in timing
Phenotype
Cognitive decline: Typical AD presentation
Memory loss: Prominent early feature
Progression: Similar rate to typical AD
Neuropathology
Plaques: Fewer dense-core plaques than other APP mutations
Oligomers: High burden of soluble Aβ oligomers
Vascular amyloid: Less severe than Flemish/Dutch mutations
Research Significance
Implications for Therapy
Anti-aggregation drugs: The Arctic mutation validates aggregation inhibitors
Oligomer-targeting therapies: Antibodies against oligomers may be effective
BACE inhibitors: May be less effective (production not increased)
Animal Models
APP Arctic mice: Show cognitive deficits with minimal plaque deposition
Demonstrate: Oligomer toxicity independent of plaque burden
Recent Research (2024-2026)
[Oral administration of arginine suppresses Aβ pathology in animal models of Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/41175945/) (2025 Dec) - Neurochemistry International
[Somatostatin therapy, neprilysin activation, and amyloid beta reduction: A novel approach for Alzheimer's treatment](https://pubmed.ncbi.nlm.nih.gov/40633205/) (2025 Aug) - Biomedicine & Pharmacotherapy
[Reactive Astrocytes with Reduced Function of Glutamate Transporters in the App(NL-G-F) Knock-in Mice](https://pubmed.ncbi.nlm.nih.gov/40421586/) (2025 Jun) - ACS Chemical Neuroscience
[Distinct Chemical Determinants are Essential for Achieving Ligands for Superior Optical Detection of Specific Amyloid-β Deposits in Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/39508558/) (2024 Dec) - ChemistryOpen
[Impairments in Spatial Representations of Place Cells and Neural rhythms in APP knock-in rat model](https://pubmed.ncbi.nlm.nih.gov/40031499/) (2024 Jul) - IEEE EMBC
Recent cryo-EM structural studies (2023) have resolved amyloid-beta filament structures from patients with the Arctic mutation, revealing distinct conformational differences from other Aβ aggregates. These structural insights explain the mutation's unique pathogenicity and may guide the development of aggregation inhibitors targeting protofibril formation.
The E22G substitution (within Aβ sequence) alters protofibril stability
Filaments show enhanced resistance to proteolytic clearance
Therapeutic Implications
The mutation's location within the Aβ peptide itself makes it a valuable model for testing therapies targeting protofibril formation and aggregation. Key therapeutic approaches include:
Aggregation Inhibitors
Small molecules targeting Aβ protofibril stabilization
[NIH National Institute on Aging - Alzheimer's Disease](https://www.nia.nih.gov/health/alzheimers)
References
[Unknown, Oral administration of arginine suppresses Aβ pathology in animal models of Alzheimer's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41175945/)
[Unknown, Somatostatin therapy, neprilysin activation, and amyloid beta reduction: A novel approach for Alzheimer's treatment (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40633205/)
[Unknown, Reactive Astrocytes with Reduced Function of Glutamate Transporters in the App(NL-G-F) Knock-in Mice (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40421586/)
[Unknown, Distinct Chemical Determinants are Essential for Achieving Ligands for Superior Optical Detection of Specific Amyloid-β Deposits in Alzheimer's Disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/39508558/)
[Unknown, Impairments in Spatial Representations of Place Cells and Neural rhythms In APP knock-in rat model (n.d.)](https://pubmed.ncbi.nlm.nih.gov/40031499/)